# Design, optimization, and ADMET evaluation of S11a-0000168202: A promising LIMK1 inhibitor for gastric cancer treatment

## TL;DR

This paper presents a new LIMK1 inhibitor, S11a-0000168202, developed for gastric cancer treatment with promising computational results.

## Contribution

The novel LIMK1 inhibitor S11a-0000168202 was designed and optimized with improved binding and ADMET properties.

## Key findings

- S11a-0000168202 showed enhanced binding stability and interactions with key LIMK1 residues.
- ADMET evaluation indicated favorable properties like moderate lipophilicity and good intestinal absorption.
- The compound remains untested experimentally, highlighting a need for further in vitro and in vivo studies.

## Abstract

This study focuses on the development and optimization of S11a-0000168202, a novel LIMK1 inhibitor with potential therapeutic applications in gastric cancer. Through scaffold hopping and structural modification of HIT100844099, S11a-0000168202 demonstrated enhanced binding stability and stronger interactions with key LIMK1 residues, including GLU-414, ILE-416, and HIS-464. Molecular dynamics simulations and MMGBSA analyses confirmed the compound’s stability, while ADMET evaluation revealed favorable properties such as moderate lipophilicity, good human intestinal absorption, and low P-glycoprotein inhibition. Despite the promising computational results, the lack of experimental validation remains a limitation. Future studies should focus on in vitro and in vivo testing to confirm S11a-0000168202’s efficacy, pharmacokinetics, and safety. This compound holds significant potential as a therapeutic agent for LIMK1-targeted gastric cancer treatment.